At Worldwide, we recognize that success in IgA neuropathy now requires differentiation versus standards of care, meaningful proteinuria reductions, and sustained eGFR preservation. Our renal team has helped sponsors meet these challenges and generate the evidence regulators, physicians, and patients expect.
We’ll connect you with the right IgA nephropathy clinical development team
Why IgA Nephropathy Programs Demand Specialized Support
We bring together centralized pathology review that protects diagnostic accuracy, harmonized renal endpoint capture across sites and central labs, and a curated network of high-performing nephrology sites that provides the flexibility to absorb high screen-failure rates. By addressing the key operational risks unique to IgA nephropathy studies, we help sponsors accelerate enrollment, safeguard data quality, and make pivotal development decisions with confidence.
UPCR, UACR, GFR, and kidney biopsies have to be captured the same way across every site and central lab. Small variability at collection compounds into endpoint risk at analysis.
Approved therapies give patients an alternative to trial participation, and screen failure runs higher than most enrollment models assume, particularly in the U.S. where competition for the same patients is heaviest.
Each new approval resets endpoint expectations and comparator choice. Designation strategy, endpoint selection and KOL engagement now sit in protocol design rather than in the first regulatory meeting.

Partnership & Approach
At Worldwide, sponsors work directly with the senior scientific, medical, and project leaders who lead our renal portfolio and are empowered to make decisions without layers of escalation. Sponsors bring deep knowledge of their asset; we bring a team with firsthand experience delivering rare renal programs through the complexities of development, enrollment, and execution. Most importantly, the experts who help shape the strategy are the same people who stay with the program through delivery.
Five years of renal delivery across 26 studies and 16 indications, including the pivotal studies behind two rare renal therapy approvals.
Nephrology Sites Across 49 Countries
A rare renal site network built around disease prevalence and long-standing investigator relationships, with 70+ pediatric nephrology sites across 13 countries alongside it.

Studies
Indications
Patients
Five years of renal delivery across more than 1,250 sites, spanning rare and reflecting five years of renal indications through every phase of development.

Enrollment Success for a Phase II Global Study
A Phase II cross-over study in biopsy-proven IgA nephropathy across 30 sites in 6 countries, delivered against higher-than-planned screen failure and a newly approved competing therapy.

Why Worldwide for IgA Nephropathy Trials
680+ nephrology sites across 49 countries, with a pre-selected site pool that gives programs room to move when screen failure rates run higher than planned.
UPCR, UACR, GFR, total kidney volume, and kidney biopsies managed consistently across sites and central labs, with central pathology covering light microscopy, electron microscopy and immunofluorescence.
Our nephrology medical and scientific team tracks FDA, EMA and MHRA guidance across rare renal indications, with endpoint strategy, designation opportunities and KOL engagement built into protocol design.
Frequently Asked Questions
We have answered the questions sponsors ask most often about IgA nephropathy programs. If yours isn’t here, our rare nephrology team is happy to help.
Central pathology review is integrated at the protocol level, covering light microscopy, electron microscopy and immunofluorescence. Biopsy interpretation and eligibility documentation are managed consistently across all sites, so the trial-entry diagnosis holds through regulatory submission. In an indication where the diagnosis is biopsy-confirmed and often revisited, that consistency is what protects the primary endpoint.
Our nephrology medical and scientific team tracks FDA, EMA and MHRA guidance closely. Proteinuria reduction is now an accepted accelerated approval surrogate with a favorable eGFR slope over 24 months serving as the definitive renal outcome, and most new programs are designed against active comparators rather than placebo. Endpoint strategy, designation opportunities including Fast Track, Breakthrough and Orphan Drug, and KOL engagement go into protocol design from the start.
Worldwide maintains long-standing relationships with nephrology KOLs and indication-specific investigator networks across rare renal indications, alongside partnerships with patient advocacy groups for education, awareness and referral. These relationships are cultivated over time, so they are in place before a program needs them.
Screen failure runs higher in IgA nephropathy than most enrollment models assume, and competition for biopsy-confirmed patients is heaviest in the U.S. A pre-selected pool of sites gives the program room to move when rates run high, supported by site-level recruitment strategies, patient education materials and patient reimbursement services. On a Phase II cross-over study, that approach closed enrollment six months ahead of schedule across 30 sites in six countries.
24-hour and first morning void collections carry much of the dropout risk in renal trials. We support them with non-spoken instructional videos, male and female collection containers, cooler backpacks for confidential transport, and at-home sample pickup where it can be arranged, alongside home health, concierge travel and patient navigator services.
Yes. We maintain a dedicated pediatric nephrology network of more than 70 sites across 13 countries, and a pediatric nephrologist sits on the medical monitoring team with 15 years in clinical practice and 20 years in rare renal research.